Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTY6OF)

Drug Name
ATI-501 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alopecia ED70 Phase 2 [1]
Cross-matching ID
PubChem CID
23585272
TTD Drug ID
DMTY6OF

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [2]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Janus kinase 3 (JAK-3) DTT JAK3 2.104 3.248 2.848 4.485
Janus kinase 1 (JAK-1) DTT JAK1 8.621 9.012 9.168 8.535
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Alopecia
ICD Disease Classification ED70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Janus kinase 1 (JAK-1) DTT JAK1 6.35E-07 -0.28 -1.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03594227) ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Aclaris Therapeutics.